WO 2004/050659 PCT/US2003/035969

-121-

## WE CLAIM:

## 1. A compound of the formula:

$$R_3$$
 $R_2$ 
 $R_1$ 

#### Formula la

5 wherein n is 1-4;

15

20

25

R<sub>1</sub> may be one or more optional substituents selected from the group consisting of: (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C2-C6)alkenyloxy, (C1-C6)alkylthio, (C1-C6)alkylsulphinyl, (C1-C6)alkylsulphonyl, (C1-C6)alkylamino, di-[(C1-C6)alkyl]amino, (C1-C6)alkoxycarbonyl, N-(C1-

C6)alkylcarbamoyl, N,N-di-[(C1-C6)alkyl]carbamoyl, (C2-C6)alkanoyl, (C2-C6)alkanoyloxy, (C2-C6)alkanoylamino, N-(C1-C6)alkyl-(C2-C6)alkanoylamino, (C3-C6)alkenoylamino, N-(C1-C6)alkyl-(C3-C6)alkenoylamino, (C3-C6)alkynoylamino, N-(C1-C6)alkyl-(C3-C6)alkyloylamino, N-(C1-C6)alkylsulphamoyl, N,N-di-[(C1-C6)alkyl]sulphamoyl, (C1-C6)alkanesulphonylamino, N-(C1-C6)alkyl-(C1-C6)alky

C6)alkanesulphonylamino, carboxamide, ethylene, thiophenyl, aminophenyl, trifluoromethyl, halo, trifluoromethoxy, hydroxymethyl, N-pyrrolidino, N-morpholino, phenylthio, (C1-C4)dialkylaminomethyl, methoxyphenyl, amino, hydroxy, carboxyl, phenyl, arylalky;

R<sub>2</sub> is selected from the group comprising unsubstituted or substituted thiophene; unsubstituted or substituted or substituted or substituted pyrazine; unsubstituted or substituted furan; unsubstituted or substituted imidazo[1,2-a]pyridine; unsubstituted or substituted benzoimidazole; unsubstituted or substituted quinoxaline; unsubstituted or substituted isoquinoline; unsubstituted or substituted benzothiazole; unsubstituted or substituted indole; unsubstituted or substituted imidazo[4,5-b]pyridine; unsubstituted or substituted imidazo[4,5-b]pyridine; unsubstituted imidazo[4,5-b]pyridine;

unsubstituted or substituted dihydrobenzofuran; unsubstituted or substituted benzofuran; unsubstituted or substituted benzo[2,1,3]thiadiazole; unsubstituted or substituted benzo[1,2,5]thiadiazole; unsubstituted or substituted pyrazolo[1,5-a]pyrimidine; unsubstituted or substituted or substituted or substituted or substituted or substituted [1,4]dioxepine; unsubstituted or substituted [1,5]naphthyridine; unsubstituted or substituted [1,6]naphthyridine; or unsubstituted or substituted [1,8]naphthyridine;

5

wherein the substitution may independently be one or more of the following: (C1-C6)alkyl; (C1-C6)alkoxy; halogen; hydroxy;nitro; amino; phenyl or substituted phenyl, wherein the phenyl may independently be substituted by 10 one or two of the following: halogen, (C1-C6)alkyl, (C1-C6)alkoxy, nitro, amino, or hydroxy;  $-(CH_2)_m R^8$ ;  $-(CH_2)_o(O)R^9$ ; -(CH<sub>2</sub>)<sub>o</sub>C(O)morpholine; 15  $-C(O)R^6$ ;  $-C(O)OR^4$ ;  $-C(O)NR^4R^5$ ; -C(O)NR<sup>4</sup>(CH<sub>2</sub>)<sub>0</sub>NR<sup>4</sup>R<sup>5</sup>; -NR<sup>4</sup>(C1-C9)alkyl; 20 -NR<sup>4</sup>C(O)(CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>  $-NR^4C(O)(CH_2)_0NR^4R^5$ ;  $-O(CH_2)_0R^7$ ; or  $-OC(O)R^4$ ; 25 wherein m is 0, 1, 2 or 3; o is 1, 2 or 3;  $R^4$  and  $R^5$  are each independently hydrogen or  $(C_1-C_6)$  alkyl; R<sup>6</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or -NR<sup>4</sup>R<sup>5</sup>; R<sup>7</sup> is hydroxy, cyano, pyrrolidine or NR<sup>4</sup>R<sup>5</sup>: 30 R<sup>8</sup> is morpholine, hydroxy, pyrrolidine, tetrahydropyran, (C1-C6)alkyl or NR<sup>4</sup>R<sup>5</sup>; R<sup>9</sup> is morpholine, pyrrolidine, tetrahydropyran, or (C1-C6)alkyl;

WO 2004/050659 PCT/US2003/035969

-123-

R<sub>3</sub> is hydrogen or (C1-C6)alkyl; and the pharmaceutically acceptable salts thereof.

5

2. A compound according to claim 1 of the formula:

$$R_2$$

10

15

25

#### Formula II

wherein n is 0 or 1;

R<sub>1</sub> is hydrogen or (C1-C4alkyl);

R<sub>2</sub> is selected from the group comprising unsubstituted or substituted thiophene; unsubstituted or substituted or substituted or substituted or substituted or substituted or substituted furan; unsubstituted or substituted imidazo[1,2-a]pyridine; unsubstituted or substituted benzoimidazole; unsubstituted or substituted quinoxaline; unsubstituted or substituted isoquinoline; unsubstituted or substituted benzothiazole; unsubstituted or substituted imidazo[4,5-b]pyridine; unsubstituted or substituted imidazo[4,5-c]pyridine; unsubstituted or substituted or substituted benzofuran; unsubstituted or substituted benzofuran; unsubstituted or substituted benzofuran; unsubstituted or substituted benzo[2,1,3]thiadiazole; unsubstituted or substituted benzo[1,2,5]thiadiazole; unsubstituted or substituted or substituted

WO 2004/050659 PCT/US2003/035969

-124-

```
wherein the substitution may independently be one or more of the following:
       (C1-C6)alkyl; (C1-C6)alkoxy; halogen; hydroxy; nitro; amino;
      phenyl or substituted phenyl, wherein the phenyl is substituted by one or two halogens;
      -(CH_2)_mR^8;
      -(CH_2)_0(O)R^9;
       -(CH<sub>2</sub>)<sub>o</sub>C(O)morpholine;
       -C(O)R^6;
       -C(O)OR^4;
       -C(O)NR^4R^5;
      -C(O)NR^4(CH_2)_oNR^4R^5;
10
       -NR<sup>4</sup>(C1-C9)alkyl;
       -NR<sup>4</sup>C(O)(CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>
       -NR^4C(O)(CH_2)_oNR^4R^5;
       -O(CH_2)_oR^7;
or -OC(O)R^4;
       wherein
       m is 0, 1, 2 or 3;
       o is 1, 2 or 3;
       R<sup>4</sup> and R<sup>5</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;
       R<sup>6</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or -NR<sup>4</sup>R<sup>5</sup>;
20
       R<sup>7</sup> ishydroxy, cyano, pyrrolidine or NR<sup>4</sup>R<sup>5</sup>;
       R<sup>8</sup> is morpholine, hydroxy, pyrrolidine, tetrahydropyran, (C1-C6)alkyl or NR<sup>4</sup>R<sup>5</sup>;
       R<sup>9</sup> is morpholine, pyrrolidine, tetrahydropyran, or (C1-C6)alkyl;
       and the pharmaceutically acceptable salts thereof.
25
```

X-16014 (PCT)

125

## 3. A compound according to Claim 1:

$$R_3$$
 $R_2$ 
 $R_1$ 

#### Formula i

wherein n is 1-4;

R<sub>1</sub> may be one or more optional substituents selected from the group consisting of: (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C2-C6)alkenyloxy, (C2-C6)alkynyloxy, (C1-C6)alkylthio, (C1-C6)alkylsulphinyl, (C1-C6)alkylsulphonyl, (C1-C6)alkylamino, di-[(C1-C6)alkyl]amino, (C1-C6)alkoxycarbonyl, N-(C1-C6)alkylcarbamoyl, N,N-di-[(C1-C6)alkyl]carbamoyl, (C2-C6)alkanoyl, (C2-C6)alkanoyloxy, (C2-C6)alkanoylamino, N-(C1-C6)alkyl-(C2-C6)alkanoylamino, (C3-C6)alkanoylamino, N-(C1-C6)alkyl-(C3-C6)alkynoylamino, N-(C1-C6)alkyl-(C3-C6)alkynoylamino, N-(C1-C6)alkylsulphamoyl, N,N-di-[(C1-C6)alkylsulphamoyl, (C1-C6)alkylsulphamoyl, N,N-di-[(C1-C6)alkylsulphamoyl, (C1-C6)alkylsulphamoyl, aminophenyl, trifluoromethyl, halo, trifluoromethoxy, hydroxymethyl, N-pyrrolidino, N-morpholino, phenylthio, (C1-C4)dialkylaminomethyl, methoxyphenyl, amino, hydroxy, carboxyl, phenyl, arylalkyl;

R<sub>2</sub> is selected from the group comprising oxazole; benzo[2,1,3]thiadiazole; quinoxaline; 1*H*-imidazo[4,5-c]pyridine; imidazo[1,2-a]pyridine; indole; pyrazine; dihydrobenzofuran; furan; thiophene; isoquinoline; benzofuran; benzothiazole; 3,4-dihydro-2*H*-benzo[b][1,4]dioxepine; 1*H*-imidazo[4,5-b]pyridine; pyrazolo[1,5-a]pyrimidine; oxazolo[4,5-b]pyridine; 1*H*-benzoimidazole; [1,8]naphthyridine; or [1,5]naphthyridine;

R<sub>3</sub> may be one or more optional substituents selected from the group consisting of (C1-C6 alkyl);

and the pharmaceutically acceptable salts thereof.

# 4. A compound according to claim 2 of the formula:

$$R_a$$

Formula III

wherein:

5

R<sub>1</sub> is hydrogen or methyl;

Ra is hydrogen;

- 10 -CH<sub>2</sub> N-morpholino;
  - -CH<sub>2</sub>C(O)N-morpolino;
  - -C(O)OCH<sub>2</sub>CH<sub>3</sub>;
  - -C(O)NH(CH<sub>2</sub>)<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>;
  - -NHCH(CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>CH(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>;
- 15 -NHC(O)CH<sub>3</sub>;
  - -C(O)NH<sub>2</sub>;
  - 4-chlorophenyl;

and the pharmaceutically acceptable salts thereof.

5. A compound according to claim 2 of the formula:

Formula IV

wherein:

R<sub>1</sub> is hydrogen or methyl;

5 R<sub>b</sub> is hydrogen;

-methyl;

10

-(CH<sub>2</sub>)<sub>3</sub>O-tetrahydropyran;

and the pharmaceutically acceptable salts thereof.

6. A compound according to claim 2 of the formula:

Formula V

wherein:

R<sub>1</sub> is hydrogen or methyl;

R<sub>c</sub> is hydrogen;

15 -methyl;

-(CH<sub>2</sub>)3OH;

15

20

25

30

X-16014 (PCT)

-128-

-(CH<sub>2</sub>)<sub>3</sub>N(CH<sub>3</sub>)<sub>2</sub>;

-(CH<sub>2</sub>)<sub>3</sub>N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>;

-(CH<sub>2</sub>)X,

wherein X is either N-morpholino, N-pyrrolidine or N-piperidine;

- 5 and the pharmaceutically acceptable salts thereof.
  - 7. A compound according to claim 1 selected from the group consisting of:
    - a) 2-(Pyridin-2-yl)-3-(thiophen-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
    - b) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole;
    - c) 3-(2-Phenyl-oxazol-5-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
    - d) 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzo[2,1,3]thiadiazole;
    - e) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzo[2,1,3]thiadiazole;
    - f) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline;
    - g) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline;
    - h) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-imidazo[4,5-b]pyridine;
    - i) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-imidazo[4,5-c]pyridine;
    - j) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1Hbenzoimidazole;
    - k) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-oxazolo[4,5-b]pyridine;
    - 2-Dimethylamino-N-[6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,8]naphthyridin-2-yl]-acetamide;
    - m) 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl][1,8]naphthyridine;

10

15

20

25

- n) 2-(Pyridin-2-yl)-3-(imidazo[1,2-a]pyridin-6-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- o) 7-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-isoquinoline;
- p) 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-isoquinoline;
- q) 3-(4-Fluoro-benzofuran-7-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- r) 2-Methyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzothiazole;
- s) 2-Methyl-5-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzothiazole;
- t) 3-(4-Fluoro-benzofuran-7-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- u) 7-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-isoquinoline;
- v) 1-Methyl-5-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole;
- w) 1-Methyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]1H
  indole;
- x) 3-(Pyrazin-2-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- y) 2-(6-Methyl-pyridin-2-yl)-3-(pyrazin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- z) 3-(2,3-Dihydro-benzofuran-5-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- aa) 3-(Furan-3-yl-2)-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- bb) 3-(Furan-3-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- cc) 2-(6-Methyl-pyridin-2-yl)-3-(thiophen-3-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;

- dd) 3-(Benzofuran-5-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- ee) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-pyrazolo[1,5-a]pyrimidine;

10

15

20

25

- ff) 3-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- gg) 3-Morpholin-4-ylmethyl-6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine;
- hh) 1-Morpholin-4-yl-2-[6-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-imidazo[1,2-a]pyridin-3-yl]-ethanone;
- ii) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine-3-carboxylic acid;
- jj) 6-[2-(Pyridin-2-yl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridin-3-yl]-imidazo[1,2-a]pyridine;
- kk) 1-Morpholin-4-yl-2-[6-(2-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-ethanone;
- 1l) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide;
- mm) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester;
- nn) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine-2-carboxylic acid amide;
- oo) 8-Fluoro-6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine;
- pp) [6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine;
- qq) N-[6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridin-3-yl]-acetamide;
- rr) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine-3-carboxylic Acid Amide;

10

15

20

25

- ss) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine-2-carboxylic Acid (2-Dimethylamino-ethyl)-amide;
- tt) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine-3-carboxylic Acid Amide;
- uu) 7-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine;
- vv) 3-(4-Chloro-phenyl)-6-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-imidazo[1,2-a]pyridine;
- ww) 5-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole;
- xx) 1-Methyl-6-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole;
- yy) 1-Methyl-6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole;
- zz) 1-Methyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole:
- aaa) 1-Methyl-5-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole;
- bbb) 5-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1H-benzoimidazole;
- ccc) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1H-benzoimidazole;
- ddd) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1H-benzoimidazole;
- eee) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1H-benzoimidazole;
- fff) 2-{7-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-pyrido[2,3-b]pyrazin-2-yloxy}-ethanol;
- ggg) 7-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-quinoxalin-2-one;

WO 2004/050659

5

10

15

20

25

- hhh) 3-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl] [1,5]naphthyridine;
- iii) 3-[6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzoimidazol-1-yl]-propan-1-ol;
- jjj) 3-[6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzoimidazol-1-yl]-propan-1-ol;
- kkk) Methanesulfonic Acid 3-[6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzoimidazol-1-yl]-propyl Ester;
- lll) Methanesulfonic acid 3-[6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzoimidazol-1-yl]-propyl ester;
- mmm) Dimethyl-[3-[6-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazol-1-yl]propyl]amine;
- nnn) Diethyl-[3-[6-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazol-1-yl]propyl]amine;
- ooo) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-(3-morpholin-4-yl-propyl)-1H-benzoimidazole;
- ppp) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-(3-pyrrolidin-1-yl-propyl)-1H-benzoimidazole;
- qqq) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-(3-piperidin-1-yl-propyl)-1H-benzoimidazole;
- rrr) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole;
- sss) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline;
- ttt) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline;
- uuu) 2-[7-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxalin-2-yloxy]-ethanol;
- vvv) 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- [1,6]naphthyridine;
- www) 6-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-isoquinoline;

10

15

20

25

- xxx) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzothiazole;
- yyy) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzothiazole;
- zzz) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzothiazol-2-ylamine;
- aaaa) 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole;
- bbbb) 3-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole;
- cccc) 3-(2,3-Dihydro-benzofuran-5-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- dddd) Acetic acid 5-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzofuran-3-yl ester;
- eeee) 3-(5-Methoxy-benzofuran-3-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- ffff) 5-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzofuran-2-carboxylic acid;
- gggg) 3-(Benzofuran-2-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- hhhh) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-pyrazolo[1,5-a]pyrimidine;
- iiii) 5-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-pyrazolo[1,5-a]pyrimidine;
- jjjj) 5-[2-(Pyridin-2-yl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridin-3-yl]-pyrazolo[1,5-a]pyrimidine;
- kkkk) 8-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- [1,6]naphthyridine;
- llll) 3-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-pyrazolo[1,5-a]pyrimidine;
- mmmm) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- [1,5]naphthyridine;

- nnnn) 2-Chloro-7-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline;
- oooo) Dimethyl-(2-{7-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxalin-2-yloxy}-ethyl)-amine;
- pppp) Dimethyl-(2-{7-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxalin-2-yloxy}-propyl)-amine;
- qqqq) 7-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline-2-carboxylic acid amide;

and the pharmaceutically acceptable salts thereof.

10

15

20

25

30

- 8. A compound according to claim 3 selected from the goup consisting of:
  - a. 3-(2-Phenyl-oxazol-5-yl)-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - b. 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-benzo[2,1,3]thiadiazole.
  - c. 5-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)benzo[2,1,3]thiadiazole.
  - d. 6-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinoxaline.
  - e. 2-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H-imidazo[4,5-c]pyridine.
  - f. 2-(pyridin-2-yl)-3-(imidazo[1,2-a]pyridin-6-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - g. 7-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-isoquinoline.
  - h. 3-(4-fluoro-benzofuran-7-yl)-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - i. 2-methyl-5-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-benzothiazole.
  - j. 2-methyl-5-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzothiazole.

10

15

20

25

X-16014 (PCT)

-135-

- k. 3-(4-fluoro-benzofuran-7-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1.2-b]pyrazole.
- 1. 7-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-isoquinoline.
- m. 1-Methyl-5-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H-indole.
- n. 1-Methyl-5-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H indole.
- o. 3-Pyrazin-2-yl-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
- p. 2-(6-Methyl-pyridin-2-yl)-3-pyrazin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - q. 3-(2,3-dihydro-benzofuran-5-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - r. 3-Furan-3-yl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - s. 2-(6-Methyl-pyridin-2-yl)-3-thiophen-3-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - t. 3-benzofuran-5-yl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - u. 6-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-pyrazolo[1,5-a]pyrimidine.
  - v. 3-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
- 9. A pharmaceutical formulation comprising a compound according to any one of Claims 1 to 8 or the pharmaceutically acceptable salt or ester thereof together with a pharmaceutically acceptable diluent or carrier.
- 10. Use of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt or ester thereof, in the manufacture of a medicament for the treatment of cancer, fibrosis, restenosis, wound healing, HIV infection, alzheimer's disease and/or atherosclerosis.

X-16014 (PCT)

-136-

- 11. The method of treating cancer which comprises administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt or ester thereof.
- 12. Use of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt or ester thereof, in combination with any other anti-cancer agent in the manufacture of a medicament for the treatment of cancer.
- 13. The method of treating cancer which comprises of administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt or ester thereof in combination with any other anti-cancer agent.